CoChat
Sign Up
Cited by 10

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Cdc6 contributes to abrogating the G1 checkpoint under hypoxic conditions in HPV E7 expressing cells

Chen, Hanxiang, Zhang, Qishu, Qiao, Lijun, Fan, Xueli, Zhang, Weifang, Zhao, Weiming, Chen, Jason J.·2017·Scientific Reports
DOI 10.1038/s41598-017-03060-wPMC PMC5462782
Open this paper in CoChat — free account

Abstract

The human papillomavirus (HPV) plays a central role in cervical carcinogenesis and its oncogene E7 is essential in this process. We showed here that E7 abrogated the G1 cell cycle checkpoint under hypoxia and analyzed key cell cycle related proteins for their potential role in this process. To further explore the mechanism by which E7 bypasses hypoxia-induced G1 arrest, we applied a proteomic approach and used mass spectrometry to search for proteins that are differentially expressed in E7 expressing cells under hypoxia. Among differentially expressed proteins identified, Cdc6 is a DNA replication initiation factor and exhibits oncogenic activities when overexpressed. We have recently demonstrated that Cdc6 was required for E7-induced re-replication. Significantly, here we showed that Cdc6 played a role in E7-mediated G1 checkpoint abrogation under hypoxic condition, and the function could possibly be independent from its role in DNA replication initiation. This study uncovered a new function of Cdc6 in regulating cell cycle progression and has important implications in HPV-associated cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-03060-w

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HPV-16 E7 abrogates hypoxia-induced G1 arrest. (a) RPE1 E7 cells were treated with hypoxia mimic drug DFO or CoCl2 at different concentrations for 72 hours, cell viability was determined using CCK8 assay. Data from a representative of 3 experiments are shown. (b) RPE1 vector and RPE1 E7 cells were incubated in hypoxic chamber at 1% oxygen or with 200 μM DFO for 8 hours, respectively. Cells were stained by PI and examined by flow cytometry. Data from a representative of 4 experiments are shown (Upper panel) and are summarized (Lower panel). (c) RPE1 vector and E7 expressing cells were treated with 200 μM DFO for 6 hours and labeled with 20 nM BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 4 experiments are shown (Upper panel) and the percentage of BrdU-positive cells was gated. Data are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 1 HPV-16 E7 abrogates hypoxia-induced G1 arrest. (a) RPE1 E7 cells were treated with hypoxia mimic drug DFO or CoCl2 at different concentrations for 72 hours, cell viability was determined using CCK8 assay. Data from a representative of 3 experiments are shown. (b) RPE1 vector and RPE1 E7 cells were incubated in hypoxic chamber at 1% oxygen or with 200 μM DFO for 8 hours, respectively. Cells were stained by PI and examined by flow cytometry. Data from a representative of 4 experiments are shown (Upper panel) and are summarized (Lower panel). (c) RPE1 vector and E7 expressing cells were treated with 200 μM DFO for 6 hours and labeled with 20 nM BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 4 experiments are shown (Upper panel) and the percentage of BrdU-positive cells was gated. Data are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 2 Hypoxia leads to G1 arrest in HPV-16 E7 knockdown cervical cancer cells. HPV-16 positive CaSki cells were transfected with siRNAs targeting E7 or E6 (siRNA198 or siRNA209). (a) Forty-eight hours later, the steady-state levels of p53 and pRb were examined by Immunoblotting (full-length blots are presented in Supplementary Figure 1). (b) Thirty-six hours post-transfection, the mRNA levels of HPV-16 E6 and HPV-16 E7 were determined by RT-qPCR. (c) Twenty-four hours post-transfection, cells were treated with 200 μM DFO for 8 hours. Cells were stained with PI and analyzed by flow cytometry. A representative experiment of 3 is shown (Upper panel) and summarized (Lower panel). (d) Twenty-four hours after transfection, cells were treated with 200 μM DFO for 6 hours and then labeled with BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 3 experiments are shown (Upper panel) and the percentage of BrdU-positive cells was gated. Mean percentage of BrdU positive CaSki cells are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2 Hypoxia leads to G1 arrest in HPV-16 E7 knockdown cervical cancer cells. HPV-16 positive CaSki cells were transfected with siRNAs targeting E7 or E6 (siRNA198 or siRNA209). (a) Forty-eight hours later, the steady-state levels of p53 and pRb were examined by Immunoblotting (full-length blots are presented in Supplementary Figure 1). (b) Thirty-six hours post-transfection, the mRNA levels of HPV-16 E6 and HPV-16 E7 were determined by RT-qPCR. (c) Twenty-four hours post-transfection, cells were treated with 200 μM DFO for 8 hours. Cells were stained with PI and analyzed by flow cytometry. A representative experiment of 3 is shown (Upper panel) and summarized (Lower panel). (d) Twenty-four hours after transfection, cells were treated with 200 μM DFO for 6 hours and then labeled with BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 3 experiments are shown (Upper panel) and the percentage of BrdU-positive cells was gated. Mean percentage of BrdU positive CaSki cells are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 3 Expression of cell cycle-related proteins under hypoxic conditions. The steady-state levels of HIF-1α, p53, p21, p27, Cdk1, Cdk2, Cdk4, Cdk6 and cyclinA in RPE1 cells treated with 200 μM DFO (a) or 1% O2 chamber (b) were examined by immunoblotting (Left panels) (original blots are presented in Supplementary Figure 2) and quantified (Right panels). A representative of 3 independent experiments is shown. (c) The mRNA level of HIF-1α, Cdk1 and Cdk2 were detected by RT-qPCR. GAPDH was used as a control. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3 Expression of cell cycle-related proteins under hypoxic conditions. The steady-state levels of HIF-1α, p53, p21, p27, Cdk1, Cdk2, Cdk4, Cdk6 and cyclinA in RPE1 cells treated with 200 μM DFO (a) or 1% O2 chamber (b) were examined by immunoblotting (Left panels) (original blots are presented in Supplementary Figure 2) and quantified (Right panels). A representative of 3 independent experiments is shown. (c) The mRNA level of HIF-1α, Cdk1 and Cdk2 were detected by RT-qPCR. GAPDH was used as a control. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY · PubMed Central
Figure 4 Label-free mass spectrometry quantification of RPE1 vector and E7 expressing cells under hypoxia. (a) RPE1 vector and E7 expressing cells treated with 200 μM DFO were prepared for mass spectrometry. Functional classification of differentially expressed proteins that were quantified by M.S. (b) Expression level of Cdc6 in vector and E7 expressing cells under hypoxia was determined by M.S. (c) Verification of Cdc6 steady-state level in vector and E7 expressing cells treated in hypoxic chamber at 1% oxygen by immunoblotting (original blots are presented in Supplementary Figure 3). (d) Verification of Cdc6 mRNA level in vector and E7 expressing cells treated with 200 μM DFO by RT-qPCR. Error bars reflected the standard error of the mean. *P < 0.05.
Figure 4 Label-free mass spectrometry quantification of RPE1 vector and E7 expressing cells under hypoxia. (a) RPE1 vector and E7 expressing cells treated with 200 μM DFO were prepared for mass spectrometry. Functional classification of differentially expressed proteins that were quantified by M.S. (b) Expression level of Cdc6 in vector and E7 expressing cells under hypoxia was determined by M.S. (c) Verification of Cdc6 steady-state level in vector and E7 expressing cells treated in hypoxic chamber at 1% oxygen by immunoblotting (original blots are presented in Supplementary Figure 3). (d) Verification of Cdc6 mRNA level in vector and E7 expressing cells treated with 200 μM DFO by RT-qPCR. Error bars reflected the standard error of the mean. *P < 0.05.CC BY · PubMed Central
Figure 5 Cdc6 is important for E7 expressing cells to alleviate G1 arrest under hypoxia. (a) Cdc6 in RPE1 E7 cells was knocked down by siRNA at indicated doses and analyzed by immunoblotting (Upper panel) (original blots are presented in Supplementary Figure 3) and RT-qPCR (Lower panel, 3 nM siRNA was used). (b) RPE1 E7 cells were transfected with either Cdc6 or negative control siRNA. Cells were treated with 200 μM DFO 24 hours post-transfection and cultured for an additional 8 hours, stained with PI and analyzed by flow cytometry. A representative experiment of 3 is shown (Upper panel) and summarized (Lower panel). (c) RPE1 E7 cells were transfected with either Cdc6 or negative control siRNA. Twenty-four hours later, cells were treated with 200 μM DFO for 6 hours and then labeled with BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 3 experiments are shown (Upper panel). Data are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01.
Figure 5 Cdc6 is important for E7 expressing cells to alleviate G1 arrest under hypoxia. (a) Cdc6 in RPE1 E7 cells was knocked down by siRNA at indicated doses and analyzed by immunoblotting (Upper panel) (original blots are presented in Supplementary Figure 3) and RT-qPCR (Lower panel, 3 nM siRNA was used). (b) RPE1 E7 cells were transfected with either Cdc6 or negative control siRNA. Cells were treated with 200 μM DFO 24 hours post-transfection and cultured for an additional 8 hours, stained with PI and analyzed by flow cytometry. A representative experiment of 3 is shown (Upper panel) and summarized (Lower panel). (c) RPE1 E7 cells were transfected with either Cdc6 or negative control siRNA. Twenty-four hours later, cells were treated with 200 μM DFO for 6 hours and then labeled with BrdU for 2 additional hours. Cells were stained with anti-BrdU antibody, counterstained with 7-AAD, analyzed by flow cytometry. Data from a representative of 3 experiments are shown (Upper panel). Data are summarized (Lower panel). Error bars reflected the standard error of the mean. *P < 0.05; **P < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 52

  1. zur Hausen, H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 384, 260–265 (2009). · DOI · Paper page
  2. Baseman, J. G. & Koutsky, L. A. The epidemiology of human papillomavirus infections. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 32(Suppl 1), S16–24 (2005). · DOI
  3. Van Doorslaer, K. et al. The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic acids research. 41, D571–578 (2013). · DOI
  4. de Villiers, E. M. Cross-roads in the classification of papillomaviruses. Virology. 445, 2–10 (2013). · DOI
  5. Burd, E. M. Human papillomavirus and cervical cancer. Clinical microbiology reviews. 16, 1–17 (2003). · DOI · Paper page
  6. Gao, G. et al. A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. International journal of cancer. 132, 882–890 (2013). · DOI
  7. Banerjee, N. S. et al. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. Journal of virology. 80, 6517–6524 (2006). · DOI
  8. Chen, J. J., Reid, C. E., Band, V. & Androphy, E. J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science (New York, N.Y.). 269, 529–531 (1995). · DOI · Paper page
  9. Dyson, N., Howley, P. M., Munger, K. & Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (New York, N.Y.). 243, 934–937 (1989). · DOI · Paper page
  10. Johnson, D. G., Schwarz, J. K., Cress, W. D. & Nevins, J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 365, 349–352 (1993). · DOI
  11. Chen, J. J. Genomic Instability Induced By Human Papillomavirus Oncogenes. North American journal of medicine & science. 3, 43–47 (2010). · DOI
  12. Shin, M. K., Sage, J. & Lambert, P. F. Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Cancer research. 72, 5418–5427 (2012). · DOI
  13. Demers, G. W., Espling, E., Harry, J. B., Etscheid, B. G. & Galloway, D. A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. Journal of virology. 70, 6862–6869 (1996). · DOI
  14. Fan, X. & Chen, J. J. Role of Cdk1 in DNA damage-induced G1 checkpoint abrogation by the human papillomavirus E7 oncogene. Cell cycle (Georgetown, Tex.). 13, 3249–3259 (2014). · DOI
  15. Zhou, Y. et al. Role of WDHD1 in Human Papillomavirus-Mediated Oncogenesis Identified by Transcriptional Profiling of E7-Expressing Cells. Journal of virology. 90, 6071–6084 (2016). · DOI
  16. Borlado, L. R. & Mendez, J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis. 29, 237–243 (2008). · DOI
  17. Cocker, J. H., Piatti, S., Santocanale, C., Nasmyth, K. & Diffley, J. F. An essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast. Nature. 379, 180–182 (1996). · DOI
  18. Kan, Q., Jinno, S., Yamamoto, H., Kobayashi, K. & Okayama, H. ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6. Proceedings of the National Academy of Sciences of the United States of America. 105, 4757–4762 (2008). · DOI · Paper page
  19. Uranbileg, B. et al. Cdc6 protein activates p27KIP1-bound Cdk2 protein only after the bound p27 protein undergoes C-terminal phosphorylation. The Journal of biological chemistry. 287, 6275–6283 (2012). · DOI · Paper page
  20. Lau, E., Zhu, C., Abraham, R. T. & Jiang, W. The functional role of Cdc6 in S-G2/M in mammalian cells. EMBO reports. 7, 425–430 (2006). · DOI
  21. Hateboer, G. et al. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Molecular and cellular biology. 18, 6679–6697 (1998). · DOI
  22. Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature. 440, 702–706 (2006). · DOI
  23. Bonds, L., Baker, P., Gup, C. & Shroyer, K. R. Immunohistochemical localization of cdc6 in squamous and glandular neoplasia of the uterine cervix. Archives of pathology & laboratory medicine. 126, 1164–1168 (2002). · DOI
  24. Fan, X., Zhou, Y. & Chen, J. J. Role of Cdc6 in re-replication in cells expressing human papillomavirus E7 oncogene. Carcinogenesis. 37, 799–809 (2016). · DOI · Paper page
  25. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer research. 59, 5830–5835 (1999).
  26. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature medicine. 9, 677–684 (2003). · DOI · Paper page
  27. Cho, Y. S. et al. HIF-1alpha controls keratinocyte proliferation by up-regulating p21(WAF1/Cip1). Biochimica et biophysica acta. 1783, 323–333 (2008). · DOI
  28. Gardner, L. B. et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. The Journal of biological chemistry. 276, 7919–7926 (2001). · DOI
  29. Bodily, J. M., Mehta, K. P. & Laimins, L. A. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer research. 71, 1187–1195 (2011). · DOI · Paper page
  30. Nakamura, M. et al. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology. 387, 442–448 (2009). · DOI
  31. Rodolico, V. et al. Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein. Infectious agents and cancer. 6, 18 (2011). · DOI
  32. Moon, S. U. et al. The expression of human papillomavirus type 16 (HPV16 E7) induces cell cycle arrest and apoptosis in radiation and hypoxia resistant glioblastoma cells. Molecular medicine reports. 4, 1247–1253 (2011). · DOI
  33. Bagwell, C. B. et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry. 46, 121–135 (2001). · DOI
  34. Zhou, N., Yuan, S., Wang, R., Zhang, W. & Chen, J. J. Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence. Oncotarget. 6, 30745–30761 (2015). · DOI
  35. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer cell. 11, 335–347 (2007). · DOI · Paper page
  36. Goda, N. et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Molecular and cellular biology. 23, 359–369 (2003). · DOI
  37. Gordan, J. D., Thompson, C. B. & Simon, M. C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer cell. 12, 108–113 (2007). · DOI
  38. Fan, X., Liu, Y., Heilman, S. A. & Chen, J. J. Human papillomavirus E7 induces rereplication in response to DNA damage. Journal of virology. 87, 1200–1210 (2013). · DOI
  39. Tang, S., Tao, M., McCoy, J. P. Jr. & Zheng, Z. M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. Journal of virology. 80, 4249–4263 (2006). · DOI
  40. Tang, S., Tao, M., McCoy, J. P. Jr. & Zheng, Z. M. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene. 25, 2094–2104 (2006). · DOI
  41. Zhang, W. et al. The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints. Virology. 397, 139–144 (2010). · DOI
  42. Wu, R., Abramson, A. L., Symons, M. H. & Steinberg, B. M. Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. International journal of cancer. 127, 2230–2237 (2010). · DOI
  43. Yiu, G. K. et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. The American journal of pathology. 159, 609–622 (2001). · DOI
  44. Songock, W. K., Kim, S. M. & Bodily, J. M. The human papillomavirus E7 oncoprotein as a regulator of transcription. Virus research (2016). · DOI
  45. Hu, D. et al. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo. Archives of gynecology and obstetrics. 292, 1345–1354 (2015). · DOI
  46. Roman, A. & Munger, K. The papillomavirus E7 proteins. Virology. 445, 138–168 (2013). · DOI
  47. Munger, K. et al. Mechanisms of human papillomavirus-induced oncogenesis. Journal of virology. 78, 11451–11460 (2004). · DOI · Paper page
  48. De Marco, F. Oxidative stress and HPV carcinogenesis. Viruses. 5, 708–731 (2013). · DOI
  49. Zerfass-Thome, K. et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene. 13, 2323–2330 (1996).
  50. Massimi, P. & Banks, L. Repression of p53 transcriptional activity by the HPV E7 proteins. Virology. 227, 255–259 (1997). · DOI
  51. Kelly, T. J., Nurse, P. & Forsburg, S. L. Coupling DNA replication to the cell cycle. Cold Spring Harbor symposia on quantitative biology. 58, 637–644 (1993). · DOI
  52. Tada, S. Cdt1 and geminin: role during cell cycle progression and DNA damage in higher eukaryotes. Frontiers in bioscience: a journal and virtual library. 12, 1629–1641 (2007). · DOI

Cited by

Metadata

Authors
Chen, H., Zhang, Q., Qiao, L., Fan, X., Zhang, W., Zhao, W., & Chen, J. J.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2017-06-07
Volume
7
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-017-03060-w
PMC
PMC5462782
Cited by
10
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review